Folic Acid Therapy Reduces the First Stroke Risk Associated With Hypercholesterolemia Among Hypertensive Patients

doi:10.1161/STROKEAHA.116.014578

Randomized Controlled Trial

. 2016 Nov;47(11):2805-2812.

doi: 10.1161/STROKEAHA.116.014578. Epub 2016 Oct 11.

Folic Acid Therapy Reduces the First Stroke Risk Associated With Hypercholesterolemia Among Hypertensive Patients

Xianhui Qin¹, Jianping Li¹, J David Spence¹, Yan Zhang¹, Youbao Li¹, Xiaobin Wang¹, Binyan Wang¹, Ningling Sun¹, Fang Chen¹, Jingxuan Guo¹, Delu Yin¹, Liming Sun¹, Genfu Tang¹, Mingli He¹, Jia Fu¹, Yefeng Cai¹, Xiuli Shi¹, Ping Ye¹, Hong Chen¹, Shuiping Zhao¹, Mao Chen¹, Chuanyu Gao¹, Xiangqing Kong¹, Fan Fan Hou¹, Yining Huang², Yong Huo¹

Affiliations

¹ From the Renal Division, Nanfang Hospital, Southern Medical University, National Clinical Research Center for Kidney Disease, State Key Laboratory for Organ Failure Research, Guangzhou, China (X.Q., Y.L., B.W., F.F.H.); Department of Cardiology (J.L., Y.Z., Y. Huo) and Department of Neurology (Y. Huang), Peking University First Hospital, Beijing, China; Stroke Prevention and Atherosclerosis Research Centre, Robarts Research Institute, University of Western Ontario, London, Canada (J.D.S.); Department of Population, Family and Reproductive Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD (X.W.); Department of Cardiology, Peking University People's Hospital, Beijing, China (N.S., H.C.); Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, China (F.C.); Department of Cardiology, Peking University Third Hospital, Beijing, China (J.G.); Department of Cardiology, First People's Hospital, Lianyungang, China (D.Y.); Department of Cardiology, Second People's Hospital, Lianyungang, China (L.S.); Institute for Biomedicine, School of Health Administration (G.T.) and Department of Neurology, First Affiliated Hospital (J.F., X.S.), Anhui Medical University, Hefei, China; Department of Neurology, First People's Hospital, Lianyungang, China (M.H.); Department of Neurology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China (Y.C.); Department of Geriatric Cardiology, the General Hospital of the People's Liberation Army, Beijing, China (P.Y.); Department of Cardiology, Second Xiangya Hospital, Central South University, Changsha, China (S.Z.); Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China (M.C.); Department of Cardiology, Henan Provincial People's Hospital, Zhengzhou University, Zhengzhou, China (C.G.); and Department of Cardiology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China (X.K.).
² From the Renal Division, Nanfang Hospital, Southern Medical University, National Clinical Research Center for Kidney Disease, State Key Laboratory for Organ Failure Research, Guangzhou, China (X.Q., Y.L., B.W., F.F.H.); Department of Cardiology (J.L., Y.Z., Y. Huo) and Department of Neurology (Y. Huang), Peking University First Hospital, Beijing, China; Stroke Prevention and Atherosclerosis Research Centre, Robarts Research Institute, University of Western Ontario, London, Canada (J.D.S.); Department of Population, Family and Reproductive Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD (X.W.); Department of Cardiology, Peking University People's Hospital, Beijing, China (N.S., H.C.); Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, China (F.C.); Department of Cardiology, Peking University Third Hospital, Beijing, China (J.G.); Department of Cardiology, First People's Hospital, Lianyungang, China (D.Y.); Department of Cardiology, Second People's Hospital, Lianyungang, China (L.S.); Institute for Biomedicine, School of Health Administration (G.T.) and Department of Neurology, First Affiliated Hospital (J.F., X.S.), Anhui Medical University, Hefei, China; Department of Neurology, First People's Hospital, Lianyungang, China (M.H.); Department of Neurology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China (Y.C.); Department of Geriatric Cardiology, the General Hospital of the People's Liberation Army, Beijing, China (P.Y.); Department of Cardiology, Second Xiangya Hospital, Central South University, Changsha, China (S.Z.); Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China (M.C.); Department of Cardiology, Henan Provincial People's Hospital, Zhengzhou University, Zhengzhou, China (C.G.); and Department of Cardiology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China (X.K.). ynhuang@sina.com huoyong@263.net.cn.

PMID: 27729579
DOI: 10.1161/STROKEAHA.116.014578

Randomized Controlled Trial

Folic Acid Therapy Reduces the First Stroke Risk Associated With Hypercholesterolemia Among Hypertensive Patients

Xianhui Qin et al. Stroke. 2016 Nov.

. 2016 Nov;47(11):2805-2812.

doi: 10.1161/STROKEAHA.116.014578. Epub 2016 Oct 11.

Authors

Affiliations

¹ From the Renal Division, Nanfang Hospital, Southern Medical University, National Clinical Research Center for Kidney Disease, State Key Laboratory for Organ Failure Research, Guangzhou, China (X.Q., Y.L., B.W., F.F.H.); Department of Cardiology (J.L., Y.Z., Y. Huo) and Department of Neurology (Y. Huang), Peking University First Hospital, Beijing, China; Stroke Prevention and Atherosclerosis Research Centre, Robarts Research Institute, University of Western Ontario, London, Canada (J.D.S.); Department of Population, Family and Reproductive Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD (X.W.); Department of Cardiology, Peking University People's Hospital, Beijing, China (N.S., H.C.); Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, China (F.C.); Department of Cardiology, Peking University Third Hospital, Beijing, China (J.G.); Department of Cardiology, First People's Hospital, Lianyungang, China (D.Y.); Department of Cardiology, Second People's Hospital, Lianyungang, China (L.S.); Institute for Biomedicine, School of Health Administration (G.T.) and Department of Neurology, First Affiliated Hospital (J.F., X.S.), Anhui Medical University, Hefei, China; Department of Neurology, First People's Hospital, Lianyungang, China (M.H.); Department of Neurology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China (Y.C.); Department of Geriatric Cardiology, the General Hospital of the People's Liberation Army, Beijing, China (P.Y.); Department of Cardiology, Second Xiangya Hospital, Central South University, Changsha, China (S.Z.); Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China (M.C.); Department of Cardiology, Henan Provincial People's Hospital, Zhengzhou University, Zhengzhou, China (C.G.); and Department of Cardiology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China (X.K.).
² From the Renal Division, Nanfang Hospital, Southern Medical University, National Clinical Research Center for Kidney Disease, State Key Laboratory for Organ Failure Research, Guangzhou, China (X.Q., Y.L., B.W., F.F.H.); Department of Cardiology (J.L., Y.Z., Y. Huo) and Department of Neurology (Y. Huang), Peking University First Hospital, Beijing, China; Stroke Prevention and Atherosclerosis Research Centre, Robarts Research Institute, University of Western Ontario, London, Canada (J.D.S.); Department of Population, Family and Reproductive Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD (X.W.); Department of Cardiology, Peking University People's Hospital, Beijing, China (N.S., H.C.); Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, China (F.C.); Department of Cardiology, Peking University Third Hospital, Beijing, China (J.G.); Department of Cardiology, First People's Hospital, Lianyungang, China (D.Y.); Department of Cardiology, Second People's Hospital, Lianyungang, China (L.S.); Institute for Biomedicine, School of Health Administration (G.T.) and Department of Neurology, First Affiliated Hospital (J.F., X.S.), Anhui Medical University, Hefei, China; Department of Neurology, First People's Hospital, Lianyungang, China (M.H.); Department of Neurology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China (Y.C.); Department of Geriatric Cardiology, the General Hospital of the People's Liberation Army, Beijing, China (P.Y.); Department of Cardiology, Second Xiangya Hospital, Central South University, Changsha, China (S.Z.); Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China (M.C.); Department of Cardiology, Henan Provincial People's Hospital, Zhengzhou University, Zhengzhou, China (C.G.); and Department of Cardiology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China (X.K.). ynhuang@sina.com huoyong@263.net.cn.

PMID: 27729579
DOI: 10.1161/STROKEAHA.116.014578

Abstract

Background and purpose: We sought to determine whether folic acid supplementation can independently reduce the risk of first stroke associated with elevated total cholesterol levels in a subanalysis using data from the CSPPT (China Stroke Primary Prevention Trial), a double-blind, randomized controlled trial.

Methods: A total of 20 702 hypertensive adults without a history of major cardiovascular disease were randomly assigned to a double-blind daily treatment of an enalapril 10-mg and a folic acid 0.8-mg tablet or an enalapril 10-mg tablet alone. The primary outcome was first stroke.

Results: The median treatment duration was 4.5 years. For participants not receiving folic acid treatment (enalapril-only group), high total cholesterol (≥200 mg/dL) was an independent predictor of first stroke when compared with low total cholesterol (<200 mg/dL; 4.0% versus 2.6%; hazard ratio, 1.52; 95% confidence interval, 1.18-1.97; P=0.001). Folic acid supplementation significantly reduced the risk of first stroke among participants with high total cholesterol (4.0% in the enalapril-only group versus 2.7% in the enalapril-folic acid group; hazard ratio, 0.69; 95% confidence interval, 0.56-0.84; P<0.001; number needed to treat, 78; 95% confidence interval, 52-158), independent of baseline folate levels and other important covariates. By contrast, among participants with low total cholesterol, the risk of stroke was 2.6% in the enalapril-only group versus 2.5% in the enalapril-folic acid group (hazard ratio, 1.00; 95% confidence interval, 0.75-1.30; P=0.982). The effect was greater among participants with elevated total cholesterol (P for interaction=0.024).

Conclusions: Elevated total cholesterol levels may modify the benefits of folic acid therapy on first stroke. Folic acid supplementation reduced the risk of first stroke associated with elevated total cholesterol by 31% among hypertensive adults without a history of major cardiovascular diseases.

Clinical trial registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00794885.

Keywords: cholesterol; folic acid; hypercholesterolemia; risk factors; stroke.

PubMed Disclaimer

Cited by

A scoping review on natural cholesterol lowering supplements sold in South African pharmacies.
Lee HB, Khan R, Vally M, Orchard A. Lee HB, et al. Health SA. 2024 Feb 29;29:2299. doi: 10.4102/hsag.v29i0.2299. eCollection 2024. Health SA. 2024. PMID: 38445038 Free PMC article. Review.
Association Between Hyperhomocysteinemia Combined with Metabolic Syndrome and Higher Prevalence of Stroke in Chinese Adults Who Have Elevated Blood Pressure.
Hu F, Yu S, Li J, Zhou W, Wang T, Huang X, Bao H, Cheng X. Hu F, et al. Med Sci Monit. 2022 Jan 11;28:e934100. doi: 10.12659/MSM.934100. Med Sci Monit. 2022. PMID: 35013090 Free PMC article.
Predicting Risk of Stroke From Lab Tests Using Machine Learning Algorithms: Development and Evaluation of Prediction Models.
Alanazi EM, Abdou A, Luo J. Alanazi EM, et al. JMIR Form Res. 2021 Dec 2;5(12):e23440. doi: 10.2196/23440. JMIR Form Res. 2021. PMID: 34860663 Free PMC article.
Appraising the Causal Association of Plasma Homocysteine Levels With Atrial Fibrillation Risk: A Two-Sample Mendelian Randomization Study.
Chen S, Yang F, Xu T, Wang Y, Zhang K, Fu G, Zhang W. Chen S, et al. Front Genet. 2021 May 26;12:619536. doi: 10.3389/fgene.2021.619536. eCollection 2021. Front Genet. 2021. PMID: 34122499 Free PMC article.
The importance of homocysteine in the development of cardiovascular complications in patients with rheumatoid arthritis.
Głuszek J, Wierzowiecka M, Niklas K, Niklas A. Głuszek J, et al. Reumatologia. 2020;58(5):282-288. doi: 10.5114/reum.2020.99732. Epub 2020 Oct 12. Reumatologia. 2020. PMID: 33227081 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

Associated data

Actions
- Search in PubMed
- Search in ClinicalTrials.gov

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- Genetic Alliance
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Folic Acid Therapy Reduces the First Stroke Risk Associated With Hypercholesterolemia Among Hypertensive Patients

Affiliations

Folic Acid Therapy Reduces the First Stroke Risk Associated With Hypercholesterolemia Among Hypertensive Patients

Authors

Affiliations

Abstract

Similar articles

Cited by

Publication types

MeSH terms

Substances

Associated data

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Abstract

Similar articles

Cited by

Publication types

MeSH terms

Substances

Associated data

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical